대변 이식의 중요성 학사 논문

소개글

"대변 이식의 중요성 학사 논문"에 대한 내용입니다.

목차

1. 서론

2. 본론
1) Fecal Microbiota Transplant의 이식경로
2) 장내미생물의 이식전후
3) 장내미생물과 암
4) 암 발달과 장내 세균불균형
5) 암에서의 특이한 병원균
6) 장내 미생물과 항암치료
7) 소화기관암에서의 Fecal Microbiota Transplant

3. 고찰

4. 참고문헌

본문내용

Abstract
인간의 장은 다양한 미생물 군집이 모여 있는 곳으로, 1000종의 박테리아로 구성되었다. 장내미생물은 숙주의 영양, 면역, 대사에 관여해 숙주와 공생하며 살아가고 있다. gut dysbiosis나 몇몇의 박테리아와의 암과의 상관관계에 대해 많은 연구들이 진행되고 있다. 장내미생물이 암 치료의 효과 특히 면역 항암치료에 영향을 미친다는 연구결과가 있다. 항암치료에서 미생물의 개체군의 조정이 많은 관심을 받고 있다. 가장 효과적인 장내미생물의 조작은 건강한 기증자로부터의 fecal microbiota transplantation (FMT)이다. FMT는 Clostridium difficile 감염에 대해 놀라운 의학적 효과를 보이며 특히 Clostridium difficile 재발에 대해 치료법으로 추천하고 있다. 최근 암을 포함한 다른 질병에 관한 FMT의 치료적 가능성이 대두되고 있다. 이 논문에서 장내미생물과 암의 상관성과 항암치료, 암의 합병증에서의 FMT의 가능성에 대해 다룰 것이다.

Introduction
인간의 장은 많은 미생물의 서식지다. 인간의 장은 1000종류의 박테리아가 서식한다.(30) 장내 박테리아군집은 개개인마다 숙주의 특이성 때문에 다르다. 최근 장내 미생물 군집이 건강과 질병에 미치는 역할을 이해하려는 연구들이 진행되고 있다. 장내 미생물은 섬세한 균형을 이루고 있다.(46)

참고 자료

Abed J, Emgård JE, Zamir G, et al.2016. Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumorexpressed gal-GalNAc. Cell Host Microbe ; 20:215–25.
Bakken JS, Borody T, Brandt LJ, et al.2011.Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol ;9:1044–9.
Bajaj JS, Kakiyama G, Savidge T, et al.2018.Antibioticassociated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology ;68(4):1549–1558.
Boleij A, Hechenbleikner EM, Goodwin AC, et al.2015 The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis ;60:208–15.
Boleij A, Tjalsma H.2013 The itinerary of streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis ;13: 719–24.
Bonnet M, Buc E, Sauvanet P, et al.2014 Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res ;20:859–67.45. Boursi B, Mamtani R, Haynes K, et al.2015. Recurrent antibiotic exposure may promote cancer formation--another step in understanding the role of the human microbiota. Eur J Cancer ;51:2655–64.
Cammarota G, Ianiro G, Gasbarrini A.2014. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol48:693–702.
Cao H, Liu X, An Y, et al.2017. Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine. Sci Rep ;7:10322. Gastroenterology ;149:223–37.
Cao H, Xu M, Dong W, et al.2017 Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int J Cancer ;140:2545–56.
Cao Y, Wu K, Mehta R, et al.2018. Long-term use of antibiotics and risk of colorectal adenoma. Gut ;67:672–8.
Choi IJ, Kook MC, Kim YI, et al.2018 Helicobacter pylori therapy for the prevention of Metachronous gastric cancer. N Engl J Med ;378: 1085–95.
Coker OO, Dai Z, Nie Y, et al.2018. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut ;67:1024–32.
Costello SP, Conlon MA, Vuaran MS, et al.2015. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther ;42: 1011–8.
Cui B, Feng Q, Wang H, et al.2015. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol ; 30:51–8.
Daillère R, Vétizou M, Waldschmitt N, et al.2016 Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity ;45:931–43.
Dhiman RK, Rana B, Agrawal S, et al.2014 Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology ;147: 1327–37.e3.
Dias-Jácome E, Libânio D, Borges-Canha M, et al. 2016.Gastric microbiota and carcinogenesis: the role of non-helicobacter pylori bacteria - a systematic review. Rev Esp Enferm Dig ;108: 530–40.
Distrutti E, Monaldi L, Ricci P, et al.2016. Gut microbiota role in irritable bowel syndrome: newtherapeutic strategies. World J Gastroenterol ;22:2219–41.
Doorakkers E, Lagergren J, Engstrand L, et al.2018 Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut ;67:2092–2096.
Fan X, Alekseyenko AV, Wu J, et al.2018 Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut ;67:120–7.
Ferrere G, Wrzosek L, Cailleux F, et al.2017 Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol ;66:806–15.
Geller LT, Barzily-Rokni M, Danino T, et al.2017 Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science ;357: 1156–60.
Gopalakrishnan V, Spencer CN, Nezi L, et al.2018 Gut microbiome modulates response to anti-PD- 1 immunotherapy in melanoma patients. Science ;359:97–103.
Hsieh YY, Tung SY, Pan HY, et al.2018 Increased abundance of clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep ;8:158.
Ijssennagger N, Belzer C, Hooiveld GJ, et al.2015 Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc Natl Acad Sci USA ;112:10038–43.
Johnson CH, Dejea CM, Edler D, et al.2015. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab ;21:891–7.
Kao D, Roach B, Silva M, et al.2017. Effect of Oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2;318:1985–93.
Khan S, Imran A, Khan AA, et al.2016. Systems biology approaches for the prediction of possible role of chlamydia pneumoniae proteins in the etiology of lung cancer. PLoS One ;11: e0148530.
Kumar R, Herold JL, Schady D, et al.2017 Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog \;13:e1006440.
Lozupone CA, Stombaugh JI, Gordon JI, et al.2012. Diversity, stability and resilience of the human gut microbiota. Nature ;489:220–30.
Zhang JW, Du P, Gao J, et al.2012 Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci ; 343:199–205.
Zhou D, Pan Q, Shen F, et al.2017 Total fecal microbiota transplantation alleviates high-fat dietinduced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep ;7:1529.
Zitvogel L, Ma Y, Raoult D, et al.2018. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science ;359: 1366–70.
Ma C, Han M, Heinrich B, et al.2018 Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science; 360(6391) :eaan5931.
Michaud DS.2013 Role of bacterial infections in pancreatic cancer. Carcinogenesis;34:2193–7.
Mullish BH, Quraishi MN, Segal JP, et al.2018. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut ;67:1920–41.
Pushalkar S, Hundeyin M, Daley D, et al.2018 The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov ;8: 403–16.
Ochi A, Nguyen AH, Bedrosian AS, et al.2012 MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med ;209:1671–87.
Qin C, Zhang H, Zhao L, et al.2017 Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis. Sci China Life Sci [in press].
Rosshart SP, Vassallo BG, Angeletti D, et al.2017 Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell ; 171:1015–28.e13.
Routy B, Le CE, Derosa L, et al.2018 Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science ; 359:91–7.
Sivan A, Corrales L, Hubert N, et al.2015 Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science ; 350:1084–9.
Toprak NU, Yagci A, Gulluoglu BM, et al.2006 A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect ;12:782–6.
Viaud S, Saccheri F, Mignot G, et al.2013 The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science ;342: 971–6.
Wang F, Meng W, Wang B, et al.2014 Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett ;345:196–202.
Wang L, Cao H, Liu L, et al.2014. Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a lactobacillus rhamnosus GG-derived protein. J Biol Chem ;289:20234–44.
Wang WW, Zhang Y, Huang XB, et al.2017. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon
tetrachloride-induced acute hepatic dysfunction. World J Gastroenterol ;23:6983–94.
Wong SH, Tny K, Chow TC, et al. 2017.Quantitation of faecal fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut ;66:1441–8.
Wong SH, Zhao L, Zhang X, et al.2017. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germfree and conventional mice. Gastroenterology ;153:1621–33.e6.
Xie YH, Gao QY, Cai GX, et al.2017 Fecal clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine;25:32–40.
Yang Y, Weng W, Peng J, et al.2017 Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-B, and up-regulating expression of MicroRNA-21. Gastroenterology;152: 851–66.e24.
Yu J, Feng Q, Wong SH, et al.2017 Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2017;66:70–8.88. Jacouton E, Chain F, Sokol H, et al. Probiotic strain lactobacillus casei BL23 prevents colitisassociated colorectal cancer. Front Immunol ;8:1553.
Yu LX, Schwabe RF.2017. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol ;14:527
Yu T, Guo F, Yu Y, et al.2017 Fusobacterium nucleatum promotes Chemoresistance to colorectal cancer by modulating autophagy. Cell ;170: 548–63.e16.